TickerFacts.

Compare

Werewolf Therapeutics, Inc. vs Spero Therapeutics, Inc. vs Context Therapeutics Inc. vs Corvus Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearWerewolf Therapeutics, Inc.
HOWL		Spero Therapeutics, Inc.
SPRO		Context Therapeutics Inc.
CNTX		Corvus Pharmaceuticals, Inc.
CRVS
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$66.80Mn/an/a
Revenue growth (YoY)n/a+39.2%n/an/a
Gross marginn/an/an/an/a
Operating marginn/a9.5%n/an/a
Net marginn/a12.8%n/an/a
Net income-$60.82M$8.57M-$36.12M-$15.28M
EPS (Diluted)-$1.33$0.15-$0.38-$0.53
Operating cash flow-$60.29M-$12.62M-$26.39M-$32.80M
Free cash flow-$60.29Mn/a-$26.42M-$32.97M
Cash & equivalents$57.05M$40.27M$66.00M$4.58M
Total assets$69.40M$68.92M$68.49M$71.12M
Total liabilities$44.59M$9.90M$8.02M$9.91M
Shareholders' equity$24.80M$59.02M$60.47M$61.20M
Return on year-end equity-245.2%14.5%-59.7%-25.0%
Shares outstanding48.60M56.41M91.88M74.70M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearWerewolf Therapeutics, Inc.Spero Therapeutics, Inc.Context Therapeutics Inc.Corvus Pharmaceuticals, Inc.
Latestn/a$66.80M
Ended 2025-12-31		n/an/a
1 year earliern/a$47.98M
Ended 2024-12-31		n/an/a
2 years earliern/a$103.78M
Ended 2023-12-31		n/an/a
3 years earliern/a$53.51M
Ended 2022-12-31		n/an/a
4 years earliern/a$18.26M
Ended 2021-12-31		n/an/a